Non-Small Cell Lung Cancer Market Updates

Non-Small Cell Lung Cancer Market size was valued at USD 26.94 Billion in 2023 and is poised to grow from USD 30.68 Billion in 2024 to USD 86.94 Billion by 2032, growing at a CAGR of 13.9% during the forecast period (2025-2032).

Top Players in the Global Non-Small Cell Lung Cancer Market  'F. Hoffmann-La Roche Ltd. (Switzerland) ', 'AstraZeneca (United Kingdom) ', 'Bristol-Myers Squibb Company (United States) ', 'Merck & Co., Inc. (United States) ', 'Novartis AG (Switzerland) ', 'Pfizer Inc. (United States) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'Bayer AG (Germany) ', 'Eli Lilly and Company (United States) ', 'GlaxoSmithKline plc (United Kingdom) ', 'Sanofi (France) ', 'AbbVie Inc. (United States) ', 'Johnson & Johnson (United States) ', 'Gilead Sciences, Inc. (United States) ', 'Amgen Inc. (United States) ', 'Boehringer Ingelheim GmbH (Germany) ', 'Daiichi Sankyo Company, Limited (Japan) ', 'Astellas Pharma Inc. (Japan) ', 'Biogen Inc. (United States) ', 'Regeneron Pharmaceuticals, Inc. (United States)'

Among the factors driving the growth of the NSCLC market are the rising rates of lung cancer caused by smoking, air pollution (asbestos, cadmium, and radon), HIV infection, and population expansion.

The expansion of the non-small cell lung cancer treatments market is also being aided by an increase in diagnoses of non-small cell lung cancer and an increase in awareness in both developed and developing regions. The inclusion of non-small cell cancer treatments in the pipelines of leading market participants, along with increased spending by major players in research and development activities, are also propelling the market expansion internationally.

By region, the non-small cell lung cancer market is spread across North America, Europe, Asia-Pacific, and LAMEA. North America earned USD 5.6 billion in revenue from the non-small cell lung cancer therapies market in 2021, and it is projected that over the forecast period, it would hold a leading position of this market. The fact that between 80% and 85% of all occurrences of lung cancer are NSCLC is the main reason for the market's considerable and rapid expansion.